Reported Earlier, Precigen Prices $30M Public Offering Of 35,294,118 Common Stock At $0.85/Share
Reported Earlier, Precigen Prices $30M Public Offering Of 35,294,118 Common Stock At $0.85/Share
据报道，Precigen以每股0.85美元的价格定价了3500万股普通股的公开发行。
Precigen intends to use the net proceeds from the offering for advancing PRGN-2012 to regulatory approval and commercial readiness, limited clinical development of other pipeline assets, and for working capital and general corporate purposes. The net proceeds of the offering, together with Precigen's recently announced strategic reprioritization and streamlining of resources and cash on hand, are expected to fund Precigen's operations into early 2025.
Precigen拟将此次募集资金（净额）用于推进PRGN-2012的监管批准和商业准备、少量其他流水线资产的临床开发以及流动资本和一般公司用途。此次发行的净收益与Precigen最近宣布的战略重组和现金措施相结合，预计将资助Precigen运营至2025年初。